Archive for the ‘Biography’ Category
CLEAR has formed a partnership with the research arm of GroGlo, a UK-based manufacturer of high power, LED, horticultural grow lighting.
The plan is to grow cannabis under a Home Office licence for the production of cannabis oil, both as a dietary supplement and for the development of medical products. To begin with, a low-THC crop of industrial hemp will be planted. We will be using the finola strain, originally developed in Finland and known for its short stature and early flowering. Unlike hemp grown for fibre, finola is usually grown for seed and only reaches a height of 160 – 180 cm but we will be removing male plants before they produce pollen and cultivating the female plants to produce the maximum yield of oil from their flowering tops.
The low-THC oil will be marketed as a dietary supplement, commonly known as CBD oil. There is already a burgeoning market in the UK for CBD products, all of which is currently imported from Europe or the USA. In the USA, the CBD products market was said to be worth $85 million in 2015 so there is huge potential here at home. Aside from the benefit of being UK grown and processed, we anticipate achieving a CBD concentration of about 40%, which is higher than most products already on the market.
Cultivation will be in glasshouses supplemented with LED lighting. GroGlo already has an established glasshouse facility in the east of England. Initial trials will experiment with adjusting the LED technology to provide a changing blend of light wavelengths at different stages of plant growth. This is GroGlo’s area of expertise -combining LED lighting and plant sciences, including existing relationships with some of Europe’s top universities. Professor Mick Fuller, GroGlo’s director of plant science, will lead this research and development process.
During the R&D phase, CO2 extraction of oil will be carried out under laboratory conditions at universities in York and Nottingham which already have extensive experience of the process. Each crop will be measured for yield, cannabinoid and terpene content using high pressure liquid chromatography (HPLC). Safety testing will also look for the presence of heavy metals and other contaminants. The results of testing will be fed back into cultivation and extraction processes to maximise yield and quality.
It is anticipated that the first batches of low-THC oil will be ready for market in six months. We are already in discussions with potential distributors and wholesalers. The CBD market in the UK is ripe for an effective marketing campaign which could build a very substantial business for whoever gets it right.
Once we are successfully achieving our production goals with low-THC cannabis, the same testing and development process will begin with high-THC varieties of cannabis. The aim will be to produce a range of oils extracted from single strains, selectively bred and stabilised for different THC:CBD ratios.
Professor Fuller says that GroGlo lighting products “are in use worldwide to grow a range of crops, but some 60% of sales currently come from overseas users growing cannabis for legitimate medical use.” He explains that there is an emerging market for all sorts of nutritional and medicinal plant products but cannabis shows particular promise. GW Pharmaceuticals is the only UK company to enter this market and it has become a world leader, despite the current restrictive legislation. He says: “Together with CLEAR we believe we can help bring a range of safe, high quality UK-produced cannabis products to market within a matter of two to three years.”
A key issue in the development of a successful medicinal cannabis product is the method of delivery. Smoking is not an acceptable solution as inhaling the products of combustion is an unhealthy practice but one of the great benefits of cannabis smoked as medicine is very accurate self-titration. That is the effects of inhaled cannabis are felt almost instantly and so the patient knows when they have taken enough or when they need more to achieve the required analgesic effect.
The oral mucosal spray developed for Sativex is unpopular with patients, many complain of mouth sores from its use and it was developed at least as much with the objective of deterring ‘recreational’ use of the product as with delivering the medicine effectively. It strangles the therapeutic benefits of the cannabis oil of which Sativex is composed in order to comply with the concerns of the medicines regulators about ‘diversion’ of the product into what they would term ‘misuse’. Absorption of the oil is quicker through the mucous membranes of the inside of the mouth than through the gastrointestinal system but, inevitably, some of the oil is swallowed and the pharmacology of cannabis when processed through the gut and the liver is very different.
We believe the best option is a vapouriser device and our intention is to source a ‘vape pen’ of sufficient quality to operate within clinical standards of consistency and safety. Vapourising cannabis oil avoids inhaling the products of combustion but still enables accurate self-titration of dose. A vape pen would provide a handy, convenient and very effective method of consuming medicinal cannabis. However, aside from the technology itself, initial research shows that vapour is more effectively produced when the oil is blended with either vegetable glycerin (VG) or propylene glycol (PG). Establishing the correct ratio of VG or PG to the oil is another important task.
We anticipate that clinical trials for the use of cannabis oil in treating chronic pain could start within two years. We want to compare different oils, ranging from high-CBD to equal ratios of THC:CBD and high-THC content. Prior to that we have to overcome the challenges of cultivation, oil extraction, vapouriser development and assemble the necessary research team and gain ethical approval for the trials. Recruitment for the trials will start in about 18 months time. If you wish to be considered please email ‘email@example.com’ with brief details of your condition (no more than 100 words). Do not expect to hear anything for at least 12 months but your details will be passed to the research team as a potential candidate.
CLEAR is promoting this venture simply because someone needs to do something to make this happen. For all the campaigning and lobbying of MPs and ministers, at the end of the day, the plants have to be grown and the various legislative hoops have to be jumped through. We cannot wait any longer for a radical change in the law. We have to progress through the government’s regulatory regime if we want to bring real therapeutic benfit to patients.
This opportunity arises because of the vision of GroGlo’s managing director, Mike Harlington and the team of experts he has built around him. There is huge demand for legitimate medicinal cannabis products in the UK which is only going to increase with the inevitable progress towards law reform and increasing awareness of the benefits of cannabis. Together, CLEAR and GroGlo are bringing the great hope that medicinal cannabis offers closer to reality than ever before.
Following recent changes, the CLEAR executive committee is now comprised of the following people.
Medicinal Users Panel
Vicky was awarded a fellowship of CLEAR in August 2014
Graham was awarded a fellowship of CLEAR in July 2015
Derek was awarded a fellowship of CLEAR in February 2014.
He is presently on compassionate leave caring for his mother who is gravely ill.
In five years, CLEAR has transformed the UK cannabis campaign from a ragtag group of protestors into a coherent, science and evidence-based strategy. New groups pursuing similar, responsible advocacy have emerged such as the United Patients Alliance (UPA) and most recently End Our Pain (#EndOurPain). In the last three years, in government and Parliament, there has been more liaison between the campaign, ministers and senior politicians than in the last 50 years. The Liberal Democrats have formally adopted policies which are almost identical to those enshrined in CLEAR’s aims and objectives.
Fundamental to CLEAR’s work has been the publication of evidence and the development of plans based on consultation with consumers, patients, doctors, scientists, academics and other experts.
These three publications form the basis for all our work. Please download them, read them, share them and use them as widely as you can. Together they defeat all the arguments for the continuing ban on cannabis.
The most authoritative, independent, expert research on the UK cannabis market by the Independent Drug Monitoring Unit, commissioned by CLEAR in 2011.
This is the second version of a plan for the regulation of the cannabis supply chain in Britain. This version was published on 18th October 2013
The most up-to-date, comprehensive analysis of the evidence on the safety and efficacy of cannabis as medicine. Focuses on Alzheimer’s disease, cancer, chronic pain, Crohn’s disease and multiple sclerosis. Published April 2015.
If it wasn’t for the miners and steelworkers of South Wales, the UK would now be a province of the Third Reich. As it is, the disastrous incompetence of the last Labour government, topped off by out-of-touch toffs has brought us to the point where if we stay in the EU, we will be just a subsidiary of Frau Merkel’s Greater Germany.
Call them Keystone Cops, Bullingdon Club Blaggers or Carry on No 10, the loons that sit round the cabinet table in Downing Street have failed this country and should be sent packing back to their country seats. They have no idea what Britain really is and even less how to lead us into an uncertain future.
The ramifications of South Wales steel pervade our economy and our society. It has made Britain great while Blair, Brown, Cameron and the self-serving political elite have diminished us in every way: financially, socially and morally. We are a shadow of our former selves. We must wrest back control from these idiots. They are an exact parallel with overpaid Premier League footballers: utterly selfish, egotistical to the ultimate, irresponsible of everything that does not benefit them directly and despised except of the power they hold. Footballers have their brains in their feet. Our political leaders have their brains in their wallets, pension funds and the sinecures they will acquire when they leave office.
My grandfather was a South Wales steelworker. It was career progress after he first went down the mines at age 14. In 1938, my father was malnourished with rickets because he didn’t have enough food to eat. It was only that year with the build-up to war that grandad had regular shifts and the family could be properly fed. Later my father won a scholarship to Oxford. In the 80s and 90s he became one of the top commercial lawyers in the City and independently wealthy. He was the archetypal boy from the valleys made good. Such is the way that South Wales steel has built Britain and not just with girders, RSJs and driving piles for foundations. It goes much deeper than that in ways that many of the Eton-educated wasters and ponces can never understand.
We must look after our own first. It is ludicrous that we have thousand using foodbanks, we’re cutting benefits for disabled people and meanwhile we’re giving £12 billion a year away in foreign aid, £300 million to India which spends its own money on a space programme! We also pay £13 billion each year to the EU. We have to stop this madness.
Any independent nation of significance must have its own steel manufacturing capability. We are the fifth biggest economy in the world. Save our steel industry by nationalising it. It’s not socialism, it’s common sense.
Today, 8th February 2016, Peter Reynolds, president of CLEAR, met with Norman Lamb MP, Liberal Democrat spokesperson for health, for an update on the cannabis campaign.
Independent Panel of Experts on Cannabis Regulation.
The Liberal Democrats have set up an independent panel of experts to establish how a legalised market for cannabis could work in the United Kingdom. Norman Lamb wants the panel to look at evidence from Colorado, Washington State and Uruguay, where cannabis has been legalised and to make recommendations for the party to consider in the spring.
As a contribution to the panel’s work, CLEAR has provided the independent study it commissioned in 2011, ‘Taxing the UK Cannabis Market’ which establishes the most comprehensive database on the reality of cannabis in the UK. In addition, The CLEAR Plan, ‘How To Regulate Cannabis in Britain’, builds on this data to propose detailed regulations for exactly how the market could work and contribute a £6.7 billion net gain to the UK exchequer.
Imminent Launch of New Medicinal Cannabis Campaign.
Within the next few days, CLEAR, along with other cannabis law reform groups, will co-operate in the launch of probably the largest campaign for access to medicinal cannabis ever seen in the UK. The time has come when people who are suffering must be given the opportunity to stop their pain with a safe, non-toxic, proven alternative to expensive and debilitating pharmaceutical products. The intransigence of successive UK governments must be overcome and this time a strategy is in place which will work.
The CLEAR publication ‘Medicinal Cannabis:The Evidence’ has received international acclaim and is the most comprehensive and up to date review of the scientific evidence supporting the use of cannabis.
Further Development of Liberal Democrat Drugs Policy.
In 1971, when the Misuse of Drugs Act came into force there were approximately 3,000 problematic drug users in the UK. Today, 45 years on, that figure has risen to around 350,000. Norman Lamb describes this as “one of the greatest public policy disasters of all time”. Today, in a speech about the prison service, David Cameron talked of the need to tackle the most difficult social problems facing Britain. Drug crime and drug addiction is probably the single biggest factor in our prison problems and the consequences of 45 years of failed drugs policy pervades our society. As the Liberal Democrats consider this difficult issue, tackling reform of cannabis policy is the first step.
The subject of cannabis as medicine is certain to rise to the top of the UK news agenda in forthcoming weeks as a new Coronation Street storyline unfolds.
The character Izzy Armstrong (Cherylee Houston) who has Ehlers-Danlos Syndrome, will be seen suffering when her prescription medicine fails to alleviate her pain. Erica Holroyd (Claire King) will then suggest that she starts using cannabis as an alternative and ends up supplying Izzy with the drug. The programme will look at all aspects of the debate on medicinal cannabis and examine the legal implications and the far reaching consequences of Izzy’s actions for her family.
Now, three of the UK’s most important organisations in the field are joining forces to provide the media with facts, evidence and personal testimonies about medicinal cannabis.
CLEAR is the largest drugs policy reform group in the UK with nearly 600,000 followers. The British Medicinal Cannabis Campaign (BMCC) is an independent group consisting of 4,500 members, all of whom are UK-based medicinal cannabis users. UK CBD is the leading distributor of legal, cannabinoid nutraceuticals including the world famous Charlotte’s Web and Mary’s brands.
Roland Gyallay-Pap, managing director of CLEAR, commented:
“Not for the first time, but at a crucial time in the worldwide debate, the issue of medicinal cannabis will be addressed in a British soap. We have high hopes that this will stimulate the debate and bring the absurdity of the UK government’s position into sharp focus.”
Throughout Europe, the USA, Canada, Australia, Israel and South America, interest in and the use of medicinal cannabis is growing fast. The UK is now virtually isolated amongst first world countries with the stubborn refusal of government even to consider the evidence. However there is a growing clamour from politicians, scientists and doctors that it must address what is a deeply cruel and evidence-free policy. Hundreds of thousands already use medicinal cannabis and risk a criminal record just for trying to improve their health. In addition they have to deal with a criminal underworld and risk violence, contaminated and low quality product all because government refuses to take responsibility.
There is now an overwhelming body of peer-reviewed, scientific evidence on the safety and efficacy of cannabis as medicine. CLEAR published ‘Medicinal Cannabis: The Evidence’ in April 2015 which has received international acclaim and is now also available in a Spanish language edition. Download here in English or Spanish.
Individual briefings will be available on request to journalists, reporters, media organisations and other interested parties. Briefings will be led by Peter Reynolds, one of the nation’s leading experts on the science, medicine and politics of cannabis, Mark Scott, a representative of BMCC and Nicolas Ellis, founder and managing director of UK CBD.
Please contact CLEAR to arrange a briefing at your premises by appointment. Alternatively, a central London venue can be arranged on request.
My mother, Barbara Reynolds, died peacefully surrounded by her children at about 5.10pm on 29th December 2015.
She was enjoying Christmas but became ill on Boxing Day afternoon and developed pneumonia.
In the last few months she had told us all that she felt her life was complete. She was ready.
Please join us on 15th January 2016 to celebrate her wonderful life.
1.45pm. Chilterns Crematorium, Amersham, HP7 0ND